VRC-AVIDNA036-00-VP

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

H5N1 VirusInfluenza A VirusInfluenza A Virus, H5N1 SubtypeInfluenza, HumanInfluenzavirus AOrthomyxovirdaeOrthomyxoviridae

Phase 1

Safety Study of Avian Flu Vaccine

CompletedNCT00408109

National Institute of Allergy and Infectious Diseases (NIAID)H5N1 Virus, Influenza A Virus, Influenza A Virus, H5N1 Subtype +2

Start: 2006-12-04End: 2008-08-28Target: 45Updated: 2017-07-02

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

CompletedNCT00489931

National Institute of Allergy and Infectious Diseases (NIAID)H5N1 Virus, Influenza A Virus, Influenza A Virus, H5N1 Subtype +2

Start: 2007-06-18End: 2009-04-15Target: 44Updated: 2017-07-02

Vaccine for Prevention of Bird Flu

CompletedNCT00776711

National Institute of Allergy and Infectious Diseases (NIAID)Influenza, Human

Start: 2008-10-16End: 2011-01-14Updated: 2017-07-02

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

CompletedNCT01086657

National Institute of Allergy and Infectious Diseases (NIAID)Influenza A Virus, H5N1 Subtype

Start: 2010-02-25End: 2011-12-12Updated: 2017-07-02

Related Papers

A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.

2022-02-0333 citations

Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect.

2013-04-30116 citations

DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.

2013-04-3046 citations

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.

2011-10-03167 citations